Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'
Tweet Send to a Friend
BMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
